NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
AZOPT (brinzolamide) by Novartis is carbonic anhydrase inhibitors [moa]. Approved for carbonic anhydrase inhibitor [epc]. First approved in 1998.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZOPT (brinzolamide) is a topical carbonic anhydrase inhibitor ophthalmic suspension used to reduce intraocular pressure in glaucoma and ocular hypertension. It works by inhibiting carbonic anhydrase in the ciliary processes of the eye, decreasing aqueous humor production. This small-molecule eye drop is administered topically and represents a mature therapy in the glaucoma treatment armamentarium.
$22MPart D
LOE ApproachingProduct is in mature lifecycle with modest Part D spending of $22M; team size likely stable to declining as patent expiration approaches, suggesting roles focused on lifecycle extension or transition planning.
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Started Feb 2018
637 enrolled
GlaucomaOpen Angle or Ocular Hypertension
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
Started Sep 2017
1 enrolled
Glaucoma
Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Started Apr 2015
493 enrolled
Open-Angle GlaucomaOcular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Started Jun 2014
327 enrolled
GlaucomaOcular Hypertension
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
Started Mar 2012
9 enrolled
Glaucoma
Worked on AZOPT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.